tirzepatide menopause Postmenopausal women on the GLP-1 medication (Zepbound) for obesity lost more weight if they were also using hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 Tirzepatide plus hormone therapy boosts

In a safety analysis of 1,195 patients at 96 weeks, there was no increase in discontinuations or fatal or serious adverse events among patients receiving semaglutide, although gastrointestinal side effects were more common

All products on this site are for Research and Educational use only

You may also use GHK-copper as a supplement for Skin Biology cosmetics

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

Many wellness-focused peptide programs are self-pay